A consolidated class action over the EpiPen, an epinephrine auto-injector used to treat severe allergic reactions, is headed to trial—although on a more truncated antitrust claim.
U.S. District Judge Daniel Crabtree in June tossed claims brought under the U.S. Racketeer Influenced and Corrupt Organizations Act and some of the antitrust allegations against Mylan Pharmaceuticals, which sold the EpiPen, a pen-like device that treats anaphylaxis, a potentially fatal condition caused by food allergies and insect bites.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
